8 years of historical data (2017–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Stoke Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.0B | $596M | $231M | $359M | $881M | $2.1B | $509M | — | — |
| Enterprise Value | $1.9B | $470M | $42M | $248M | $738M | $1.8B | $286M | — | — |
| P/E Ratio → | -22.07 | — | — | — | — | — | — | — | — |
| P/S Ratio | 54.90 | 16.30 | 26.36 | 28.94 | — | — | — | — | — |
| P/B Ratio | 8.59 | 2.60 | 1.45 | 1.94 | 4.05 | 7.25 | 2.27 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.86 | 4.79 | 19.98 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Stoke Therapeutics, Inc. earns an operating margin of -277.3%. Operating margins have expanded from -841.2% to -277.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -45.8% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| Operating Margin | -277.3% | -277.3% | -1307.2% | -841.2% | — | — | — | — | — |
| Net Profit Margin | -243.4% | -243.4% | -1192.5% | -814.7% | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -45.8% | -45.8% | -60.8% | -50.2% | -34.1% | -20.5% | -19.6% | -24.1% | — |
| ROA | -35.6% | -35.6% | -43.2% | -40.8% | -32.0% | -19.8% | -19.2% | -22.8% | -227.9% |
| ROIC | -206.8% | -206.8% | -392.7% | -105.7% | -173.9% | -4437.6% | -3291.3% | — | — |
| ROCE | -47.3% | -47.3% | -54.4% | -46.8% | -33.9% | -20.8% | -21.6% | -24.6% | — |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $128M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.55 | -1.19 | -0.60 | -0.66 | -1.00 | -0.99 | -1.00 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($128M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
Stoke Therapeutics, Inc.'s current ratio of 5.81x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.77x to 5.81x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.81 | 5.81 | 6.99 | 7.77 | 13.37 | 25.73 | 55.12 | 43.03 | 0.51 |
| Quick Ratio | 5.81 | 5.81 | 6.99 | 7.77 | 13.37 | 25.73 | 55.12 | 43.03 | 0.51 |
| Cash Ratio | 5.41 | 5.41 | 6.53 | 7.31 | 12.83 | 25.15 | 54.25 | 42.72 | 0.48 |
| Asset Turnover | — | 0.13 | 0.04 | 0.05 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 6.99 | 2.66 | 17.30 | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Stoke Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $54M | $44M | $39M | $37M | $33M | $18M | $24M | $24M |
Compare STOK with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| STOKYou | $2B | -22.1 | — | — | 100.0% | -277.3% | -45.8% | -206.8% | — |
| ALNY | $44B | 142.9 | 81.4 | 94.7 | 81.8% | 13.5% | 73.3% | 19.1% | 5.3 |
| IONS | $13B | -34.1 | — | — | 98.3% | -40.5% | -70.7% | -12.2% | — |
| ARWR | $9B | -5186.1 | 76.1 | 55.4 | 97.1% | 11.9% | -0.5% | 7.2% | 6.9 |
| CRSP | $6B | -9.3 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
| BEAM | $3B | -35.1 | — | — | 84.0% | -274.6% | -8.1% | -33.6% | — |
| WVE | $2B | -19.9 | — | — | 100.0% | -101.9% | -77.9% | — | — |
| RNA | $2B | -3.0 | — | — | 77.9% | -3977.3% | -44.0% | -42.8% | — |
| NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| ABUS | $895M | -12.3 | — | — | 100.0% | -1236.7% | -68.8% | -75.9% | — |
| PRME | $833M | -2.8 | — | — | 100.0% | -6787.4% | -136.9% | -260.5% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 8 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how STOK stacks up against sector leader Alnylam Pharmaceuticals, Inc..
Start ComparisonStoke Therapeutics, Inc.'s current P/E ratio is -22.1x. This places it at the 50th percentile of its historical range.
Stoke Therapeutics, Inc.'s return on equity (ROE) is -45.8%. The historical average is -36.4%.
Based on historical data, Stoke Therapeutics, Inc. is trading at a P/E of -22.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Stoke Therapeutics, Inc. has 100.0% gross margin and -277.3% operating margin.